Brussels, 9 July 2010 – At its annual General Assembly held in London, the members of European Biopharmaceutical Enterprises (EBE) unanimously elected Marc de Garidel (Amgen) as the new EBE President for a 2-year term. Mr. de Garidel is Vice-President South Region of Amgen International, based in Zug, Switzerland. He had already been an active member of the EBE Board as EBE Vice-President & Treasurer since April 2006. Marc de Garidel takes over the EBE presidency from Dr. Carlo Incerti, Senior Vice President Global Market Access at Genzyme, who will continue to sit on the EBE Board as Vice-President.
Thanking EBE member company delegates upon his election, Mr. de Garidel said that he was eager to further drive the development of EBE as a strong voice for biopharmaceuticals in Europe, building on solid foundations and numerous achievements during Dr. Incerti’s successful EBE presidency for the past four years.
The new EBE President also expressed great confidence in the new, enlarged Board of Directors, which was elected to act on behalf of the 63 EBE member companies. Together with EBE members and the association’s staff based in Brussels, the Board will continue to deliver on the collective mission of fostering a favourable business and regulatory environment for biopharmaceutical companies of all sizes operating in Europe.
Top industry executives who were elected for the first time on the EBE Board of Directors include Dr. Roberto Gradnik, Executive Vice-President at Merck Serono (Switzerland); Dr. Edwin Moses, Chairman & CEO of Ablynx (Belgium); Søren Tulstrup, President & CEO of Santaris Pharma (Denmark); Dr. Ralf Schumacher, Head of Biologics Research at Roche (Switzerland); and Dr. Ignacio Faus, CEO of Palau Pharma (Spain).
For the full EBE Board list, please visit the EBE website here.
* * *